Sanofi Has EU Insulin Aspart Biosimilar Approval

Firm Comments on Pricing And Launch Plans For Rival To NovoRapid

Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.

Thumbs_Up_EU
The European Commission has formally approved Sanofi’s insulin aspart biosimilar • Source: Shutterstock

Sanofi has received formal European Commission approval granting a pan-European marketing authorization for its insulin aspart biosimilar.

The approval comes after the firm garnered a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use at the very end of April

More from Biosimilars

More from Products